JP2020511413A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020511413A5 JP2020511413A5 JP2019531805A JP2019531805A JP2020511413A5 JP 2020511413 A5 JP2020511413 A5 JP 2020511413A5 JP 2019531805 A JP2019531805 A JP 2019531805A JP 2019531805 A JP2019531805 A JP 2019531805A JP 2020511413 A5 JP2020511413 A5 JP 2020511413A5
- Authority
- JP
- Japan
- Prior art keywords
- drug
- composition according
- plasminogen
- agents
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 13
- 229940079593 drug Drugs 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 102000008186 Collagen Human genes 0.000 claims 8
- 108010035532 Collagen Proteins 0.000 claims 8
- 206010016654 Fibrosis Diseases 0.000 claims 8
- 102000013566 Plasminogen Human genes 0.000 claims 8
- 108010051456 Plasminogen Proteins 0.000 claims 8
- 229920001436 collagen Polymers 0.000 claims 8
- 230000006378 damage Effects 0.000 claims 8
- 230000008021 deposition Effects 0.000 claims 8
- 230000004761 fibrosis Effects 0.000 claims 8
- 210000004185 liver Anatomy 0.000 claims 8
- 239000002246 antineoplastic agent Substances 0.000 claims 5
- 239000002220 antihypertensive agent Substances 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 4
- 210000004369 blood Anatomy 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 208000027418 Wounds and injury Diseases 0.000 claims 3
- 239000003472 antidiabetic agent Substances 0.000 claims 3
- 229940127088 antihypertensive drug Drugs 0.000 claims 3
- 239000003524 antilipemic agent Substances 0.000 claims 3
- -1 for example Substances 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- 208000014674 injury Diseases 0.000 claims 3
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 102000007330 LDL Lipoproteins Human genes 0.000 claims 2
- 108010007622 LDL Lipoproteins Proteins 0.000 claims 2
- 230000001476 alcoholic effect Effects 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 239000003416 antiarrhythmic agent Substances 0.000 claims 2
- 239000003146 anticoagulant agent Substances 0.000 claims 2
- 229940127219 anticoagulant drug Drugs 0.000 claims 2
- 229940127218 antiplatelet drug Drugs 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000002934 diuretic Substances 0.000 claims 2
- 229940030606 diuretics Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000003527 fibrinolytic agent Substances 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 229940121354 immunomodulator Drugs 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 claims 1
- 208000018380 Chemical injury Diseases 0.000 claims 1
- 206010072268 Drug-induced liver injury Diseases 0.000 claims 1
- 206010019799 Hepatitis viral Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000001938 Plasminogen Activators Human genes 0.000 claims 1
- 108010001014 Plasminogen Activators Proteins 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 230000003288 anthiarrhythmic effect Effects 0.000 claims 1
- 230000003510 anti-fibrotic effect Effects 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000003177 cardiotonic effect Effects 0.000 claims 1
- 229940044683 chemotherapy drug Drugs 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 231100000334 hepatotoxic Toxicity 0.000 claims 1
- 230000003082 hepatotoxic effect Effects 0.000 claims 1
- 229940126904 hypoglycaemic agent Drugs 0.000 claims 1
- 239000004041 inotropic agent Substances 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 239000002445 liver protective agent Substances 0.000 claims 1
- 210000005228 liver tissue Anatomy 0.000 claims 1
- 108010087750 lysyl-plasminogen Proteins 0.000 claims 1
- 108010049112 miniplasminogen Proteins 0.000 claims 1
- 229940127126 plasminogen activator Drugs 0.000 claims 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 1
- 206010036067 polydipsia Diseases 0.000 claims 1
- 239000011251 protective drug Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
- 229940124549 vasodilator Drugs 0.000 claims 1
- 239000003071 vasodilator agent Substances 0.000 claims 1
- 201000001862 viral hepatitis Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016110174 | 2016-12-15 | ||
| CNPCT/CN2016/110174 | 2016-12-15 | ||
| PCT/CN2017/089056 WO2018107696A1 (zh) | 2016-12-15 | 2017-06-19 | 一种预防和治疗肝纤维化的方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020511413A JP2020511413A (ja) | 2020-04-16 |
| JP2020511413A5 true JP2020511413A5 (https=) | 2020-07-30 |
| JP7213552B2 JP7213552B2 (ja) | 2023-01-27 |
Family
ID=62557850
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531805A Active JP7213552B2 (ja) | 2016-12-15 | 2017-06-19 | 肝の繊維化を予防及び治療するための方法 |
| JP2019531811A Active JP7313058B2 (ja) | 2016-12-15 | 2017-06-19 | 組織器官の繊維化を予防及び治療するための方法 |
| JP2019531806A Pending JP2020502132A (ja) | 2016-12-15 | 2017-06-19 | 皮膚の繊維化を予防及び治療するための方法 |
| JP2019531808A Active JP7213553B2 (ja) | 2016-12-15 | 2017-06-19 | 肺の繊維化を予防及び治療するための方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531811A Active JP7313058B2 (ja) | 2016-12-15 | 2017-06-19 | 組織器官の繊維化を予防及び治療するための方法 |
| JP2019531806A Pending JP2020502132A (ja) | 2016-12-15 | 2017-06-19 | 皮膚の繊維化を予防及び治療するための方法 |
| JP2019531808A Active JP7213553B2 (ja) | 2016-12-15 | 2017-06-19 | 肺の繊維化を予防及び治療するための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US20190314466A1 (https=) |
| EP (4) | EP3556380A4 (https=) |
| JP (4) | JP7213552B2 (https=) |
| CN (4) | CN110139668A (https=) |
| CA (3) | CA3047174A1 (https=) |
| TW (6) | TWI670075B (https=) |
| WO (5) | WO2018107696A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7213552B2 (ja) * | 2016-12-15 | 2023-01-27 | タレンゲン インターナショナル リミテッド | 肝の繊維化を予防及び治療するための方法 |
| CA3067890A1 (en) | 2017-06-19 | 2018-12-27 | Talengen International Limited | Method for regulating and controling glp-1/glp-1r and drug |
| TWI868051B (zh) * | 2017-06-23 | 2025-01-01 | 美商波麥堤克生物治療股份有限公司 | 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療 |
| US20230081922A1 (en) * | 2020-02-11 | 2023-03-16 | Talengen International Limited | Method and drug for treating viral pneumonia |
| TWI910217B (zh) * | 2020-08-20 | 2026-01-01 | 大陸商深圳瑞健生命科學研究院有限公司 | 一種治療腫瘤的方法和藥物 |
| CN114984032B (zh) * | 2022-06-27 | 2023-07-07 | 四川大学 | Dna四面体框架核酸-绿原酸复合物及其在制备治疗肝纤维化的药物中的用途 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4645668A (en) | 1983-08-04 | 1987-02-24 | Biospecifics, Nv | Method for the prevention and treatment of scars with enzymes |
| GB8721951D0 (en) * | 1987-09-18 | 1987-10-28 | Thrombosis Research Trust | Organic compounds |
| ES2434840T3 (es) | 1995-07-27 | 2013-12-17 | Genentech, Inc. | Formulación de proteína liofilizada isotónica estable |
| US6057122A (en) | 1996-05-03 | 2000-05-02 | Abbott Laboratories | Antiangiogenic peptides polynucleotides encoding same and methods for inhibiting angiogenesis |
| JP2002510209A (ja) | 1997-06-26 | 2002-04-02 | カロリンスカ イノベイションズ アクチボラゲット | インビボで血管形成を調節することができるプラスミノーゲンのクリングルドメイン１−５ |
| WO2000010506A2 (en) | 1998-08-20 | 2000-03-02 | University Of Vermont And State Agriculture College | Angiogenesis inhibitors and uses thereof |
| US7763580B2 (en) | 1999-01-05 | 2010-07-27 | University Of Utah Research Foundation | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| AU2002239414A1 (en) | 2000-11-02 | 2002-05-27 | Bristol-Myers Squibb Company | Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors |
| MXPA00011713A (es) * | 2000-11-28 | 2002-05-31 | Tgt Lab S A De C V | Vectores recombinantes virales y no virales conteniendo el gen humano del activador de plasminogeno derivado de urocinasa y su utilidad en el tratamiento de diversos tipos de fibrosis hepatica, renal, pulmonar, pancreatica, cardiaca y cicatrices hipe |
| US7067492B2 (en) | 2001-09-06 | 2006-06-27 | Omnio Ab | Method of promoting healing of a tympanic membrane perforation |
| US20050124036A1 (en) | 2002-02-06 | 2005-06-09 | Rudy Susilo | Method for producing recombinant proteins in micro-organisms |
| MXPA04007585A (es) * | 2002-02-06 | 2005-09-20 | N Zyme Biotec Gmbh | Metodo para la produccion de proteinas recombinantes en microorganismos. |
| JP2006507297A (ja) | 2002-05-13 | 2006-03-02 | チルドレンズ・ホスピタル・ロサンジェルス | ケロイドおよび他の皮膚または内部創傷または病変における異常瘢痕形成の処置および予防 |
| CA2509170A1 (en) | 2002-12-10 | 2004-06-24 | Wyeth | Substituted 3-alkyl and 3-arylalkyl 1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| US20050250694A1 (en) * | 2003-10-10 | 2005-11-10 | Ma Jian-Xing | Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same |
| AU2005277137A1 (en) | 2004-08-23 | 2006-03-02 | Wyeth | Pyrrolo-naphthyl acids as PAI-1 inhibitors |
| US8318661B2 (en) | 2006-08-28 | 2012-11-27 | Omnio Healer Ab | Candidates against infection |
| US20100080773A1 (en) | 2008-09-26 | 2010-04-01 | Sdg, Inc. | Orally Bioavailable Lipid-Based Constructs |
| JP5539896B2 (ja) | 2007-11-29 | 2014-07-02 | グリフオルス・セラピユーテイクス・インコーポレーテツド | 組換え的に改変されたプラスミン |
| WO2009111625A2 (en) * | 2008-03-05 | 2009-09-11 | Board Of Regents, The University Of Texas System | Peptide inhibition of lung epithelial apoptosis and pulmonary fibrosis |
| KR20120050442A (ko) * | 2009-07-10 | 2012-05-18 | 쓰롬보제닉스 엔.브이. | 플라스미노겐 및 플라스민의 변이체 |
| CN101628113B (zh) * | 2009-08-18 | 2012-01-04 | 南京农业大学 | 蚯蚓纤溶酶抗肝纤维化的应用 |
| CA2779905A1 (en) | 2009-11-07 | 2011-05-12 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| EP2566514A4 (en) | 2010-05-03 | 2013-11-27 | Abbvie Inc | METHODS OF INHIBITING FIBROSIS WITH ANTI-PAI-1 ANTIBODIES |
| CN102121023B (zh) | 2010-12-22 | 2012-07-04 | 中山大学 | 突变型人纤溶酶原kringle5及其制备方法及应用 |
| EP2661493B1 (en) * | 2011-01-05 | 2016-03-30 | ThromboGenics N.V. | Plasminogen and plasmin variants |
| CN102154253A (zh) | 2011-01-06 | 2011-08-17 | 郑州大学 | 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途 |
| WO2013134781A1 (en) | 2012-03-09 | 2013-09-12 | Vascular Biosciences | Orally active, cell-penetrating homing peptide and methods of using same |
| KR101467109B1 (ko) | 2013-07-10 | 2014-12-01 | 영남대학교 산학협력단 | Ｂｉｘ02189 화합물을 유효성분으로 포함하는 폐섬유증 예방 또는 치료용 조성물 |
| HK1221725A1 (zh) * | 2013-08-13 | 2017-06-09 | Sanofi | 纤溶酶原激活剂抑制剂-1(pai-1)的抗体及其用途 |
| CN104371019B (zh) | 2013-08-13 | 2019-09-10 | 鸿运华宁（杭州）生物医药有限公司 | 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质 |
| TW201722994A (zh) | 2013-08-13 | 2017-07-01 | 賽諾菲公司 | 胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途 |
| US20160199466A1 (en) | 2013-08-20 | 2016-07-14 | Trustees Of Dartmouth College | Methods For Treating Tissue Fibrosis |
| PL3109320T3 (pl) | 2014-02-21 | 2019-08-30 | Astellas Pharma Inc. | Nowe przeciwciało anty-ludzki PAI-1 |
| PY1577621A (es) | 2014-12-19 | 2017-10-02 | Prometic Biotherapeutics Inc | Composicion farmaceutica que comprende plasminogeno y uso para el mismo |
| TWI801331B (zh) | 2015-11-03 | 2023-05-11 | 美商波麥堤克生物治療股份有限公司 | 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法 |
| CN106890320A (zh) | 2015-12-18 | 2017-06-27 | 深圳瑞健生命科学研究院有限公司 | 一种用于预防或治疗急性及慢性血栓的方法 |
| DK3391902T5 (da) | 2015-12-18 | 2024-09-23 | Talengen Int Ltd | Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati |
| ES2982294T3 (es) | 2015-12-18 | 2024-10-15 | Talengen Int Ltd | Plasminógeno para su uso en el tratamiento o prevención de lesiones nerviosas por diabetes mellitus |
| CN106890324A (zh) | 2015-12-18 | 2017-06-27 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗糖尿病肾病的方法 |
| JP6793748B2 (ja) | 2015-12-18 | 2020-12-02 | タレンゲン インターナショナル リミテッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ | 放射性および化学的損傷を予防及び治療するための方法 |
| ES2968254T3 (es) | 2015-12-18 | 2024-05-08 | Talengen Int Ltd | Plasminógeno para su uso en la prevención o el tratamiento de la trombosis aguda y la trombosis crónica |
| CN106890318A (zh) | 2015-12-18 | 2017-06-27 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗糖尿病性心脏病的新方法 |
| JP7242057B2 (ja) * | 2016-12-15 | 2023-03-20 | タレンゲン インターナショナル リミテッド | 薬物性腎損傷を予防及び治療するための方法 |
| JP7168990B2 (ja) | 2016-12-15 | 2022-11-10 | タレンゲン インターナショナル リミテッド | 肥満症を予防および治療するための方法および薬物 |
| WO2018107686A1 (zh) * | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种治疗动脉粥样硬化及其并发症的方法 |
| JP7213552B2 (ja) | 2016-12-15 | 2023-01-27 | タレンゲン インターナショナル リミテッド | 肝の繊維化を予防及び治療するための方法 |
| TWI677348B (zh) * | 2016-12-15 | 2019-11-21 | 大陸商深圳瑞健生命科學研究院有限公司 | 一種改善心臟病變的方法 |
| CN110198732A (zh) | 2016-12-15 | 2019-09-03 | 泰伦基国际有限公司 | 一种促进胰岛素受体底物-2表达的方法 |
| CA3067890A1 (en) * | 2017-06-19 | 2018-12-27 | Talengen International Limited | Method for regulating and controling glp-1/glp-1r and drug |
-
2017
- 2017-06-19 JP JP2019531805A patent/JP7213552B2/ja active Active
- 2017-06-19 US US16/470,162 patent/US20190314466A1/en not_active Abandoned
- 2017-06-19 EP EP17880059.5A patent/EP3556380A4/en active Pending
- 2017-06-19 CA CA3047174A patent/CA3047174A1/en not_active Abandoned
- 2017-06-19 TW TW106120456A patent/TWI670075B/zh active
- 2017-06-19 CN CN201780078166.7A patent/CN110139668A/zh active Pending
- 2017-06-19 EP EP17882248.2A patent/EP3556395A4/en active Pending
- 2017-06-19 EP EP17880398.7A patent/EP3556382A4/en active Pending
- 2017-06-19 WO PCT/CN2017/089056 patent/WO2018107696A1/zh not_active Ceased
- 2017-06-19 CN CN201780078169.0A patent/CN110191718A/zh active Pending
- 2017-06-19 CN CN201780078132.8A patent/CN110121358A/zh active Pending
- 2017-06-19 CA CA3046669A patent/CA3046669A1/en not_active Abandoned
- 2017-06-19 CA CA3046671A patent/CA3046671C/en active Active
- 2017-06-19 US US16/470,172 patent/US11219669B2/en active Active
- 2017-06-19 TW TW106120453A patent/TWI734798B/zh active
- 2017-06-19 TW TW106120449A patent/TWI657823B/zh active
- 2017-06-19 US US16/470,179 patent/US11154595B2/en active Active
- 2017-06-19 JP JP2019531811A patent/JP7313058B2/ja active Active
- 2017-06-19 WO PCT/CN2017/089057 patent/WO2018107697A1/zh not_active Ceased
- 2017-06-19 TW TW106120457A patent/TW201822790A/zh unknown
- 2017-06-19 US US16/470,186 patent/US11071772B2/en active Active
- 2017-06-19 TW TW106120454A patent/TWI752044B/zh active
- 2017-06-19 TW TW110101502A patent/TW202123955A/zh unknown
- 2017-06-19 CN CN201780078123.9A patent/CN110114080A/zh active Pending
- 2017-06-19 WO PCT/CN2017/089058 patent/WO2018107698A1/zh not_active Ceased
- 2017-06-19 WO PCT/CN2017/089053 patent/WO2018107693A1/zh not_active Ceased
- 2017-06-19 EP EP17881523.9A patent/EP3556389A4/en active Pending
- 2017-06-19 JP JP2019531806A patent/JP2020502132A/ja active Pending
- 2017-06-19 WO PCT/CN2017/089054 patent/WO2018107694A1/zh not_active Ceased
- 2017-06-19 JP JP2019531808A patent/JP7213553B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020511413A5 (https=) | ||
| Ou et al. | The cGAS-STING pathway: a promising immunotherapy target | |
| Le Naour et al. | Trial watch: STING agonists in cancer therapy | |
| Gujar et al. | Heating it up: Oncolytic viruses make tumors ‘hot’and suitable for checkpoint blockade immunotherapies | |
| Wollert et al. | Intracoronary autologous bone marrow cell transfer after myocardial infarction: the BOOST-2 randomised placebo-controlled clinical trial | |
| Merigan et al. | Interferon induction in man by a synthetic polyanion of defined composition | |
| Michaud et al. | Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39 | |
| D'Elia et al. | Targeting the “cytokine storm” for therapeutic benefit | |
| Huang et al. | Kanglaite stimulates anticancer immune responses and inhibits HepG2 cell transplantation-induced tumor growth | |
| Beebe et al. | Nanopulse stimulation (NPS) induces tumor ablation and immunity in orthotopic 4T1 mouse breast cancer: A review | |
| Cocco et al. | The current role of mitoxantrone in the treatment of multiple sclerosis | |
| Toro et al. | New therapeutic perspectives in the treatment of uveal melanoma: a systematic review | |
| Weintraub et al. | Advances in intravesical therapy for the treatment of non‑muscle invasive bladder cancer | |
| CN110139668A (zh) | 一种预防和治疗肝纤维化的方法 | |
| Nakashima et al. | Potent antitumor effects of combination therapy with IFNs and monocytes in mouse models of established human ovarian and melanoma tumors | |
| Liang et al. | CRISPR/Cas9 technology targeting Fas gene protects mice from Concanavalin‐a induced fulminant hepatic failure | |
| Sun et al. | PEG‐rhG‐CSF for prophylaxis of neutropenia after chemotherapy in patients with non–small cell lung cancer: A multicenter, prospective, randomized study | |
| Yoon et al. | The clinical role of interferon alpha in Philadelphia-negative myeloproliferative neoplasms | |
| Zhou et al. | Inhibitory effects of the ultrasound‑targeted microbubble destruction‑mediated herpes simplex virus‑thymidine kinase/ganciclovir system on ovarian cancer in mice | |
| Qu et al. | Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis? | |
| Sun et al. | Cationic liposome co-encapsulation of SMAC mimetic and zVAD using a novel lipid bilayer fusion loaded with MLKL-pDNA for tumour inhibition in vivo | |
| Lünenbürger et al. | Systematic analysis of the antiproliferative effects of novel and standard anticancer agents in rhabdoid tumor cell lines | |
| Wu et al. | Clinical observation of the therapeutic effects of pegylated recombinant human granulocyte colony-stimulating factor in patients with concurrent chemoradiotherapy-induced grade IV neutropenia | |
| Desikan et al. | Host-targeted therapy for tuberculosis: time to revisit the concept | |
| Zhou et al. | Protective roles of erythropoiesis-stimulating proteins in chronic heart failure with anemia |